Samsung Competitors

Stocks . Korea . 
Stock . Samsung Biologics Co
207940 Stock   929,000  29,000  3.03%   
Samsung Biologics competes with Hanjin Transportation, Daekyung Machinery, Hana Technology, Alton Sports, and Global Standard; as well as few others. The company operates under Healthcare sector and is part of Biotechnology industry. Analyzing Samsung Biologics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Samsung Biologics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Samsung Biologics Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Samsung Biologics competition on your existing holdings.
  
Hype
Prediction
LowEstimatedHigh
957,999958,000958,001
Details
Intrinsic
Valuation
LowRealHigh
862,199862,2001,053,800
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Samsung Biologics. Your research has to be compared to or analyzed against Samsung Biologics' peers to derive any actionable benefits. When done correctly, Samsung Biologics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Samsung Biologics.

Samsung Biologics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Samsung Biologics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Samsung and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Samsung Biologics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
123750
+ 0.88
299030
123750
+ 0.8
002320
058730
+ 0.76
015590
013700
+ 0.76
047040
299030
+ 0.7
002320
013700
+ 0.7
299030
  
High negative correlations   
123750
- 0.76
015590
058730
- 0.67
123750
015590
- 0.62
002320
299030
- 0.58
015590
058730
- 0.49
299030
058730
- 0.49
002320

Risk-Adjusted Indicators

There is a big difference between Samsung Stock performing well and Samsung Biologics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Samsung Biologics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Samsung Biologics Competitive Analysis

The better you understand Samsung Biologics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Samsung Biologics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Samsung Biologics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
207940 002320 015590 299030 123750 083450 058730 047040 013700
 3.03 
 929,000 
Samsung
 2.82 
 18,980 
Hanjin
 4.89 
 515.00 
Daekyung
 0.44 
 22,800 
Hana
 0.28 
 1,444 
Alton
 2.75 
 15,720 
Global
 0.57 
 3,515 
Dong
 0.81 
 3,745 
Daewoo
 1.83 
 1,279 
Camus
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Weak
Very Weak
Very Weak
Very Weak
Insignificant
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Low
Low
Low
Low
Low
Low
Below Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Cautious Hold
Sell
Current Ratio
N/A
N/A
N/A
N/A
1.35
2.92
N/A
N/A
N/A
Net Asset
7.97 T
N/A
N/A
N/A
45.54 B
206.24 B
N/A
10.46 T
195.06 B
Profit Margin
0.2
N/A
N/A
N/A
0.11
0.12
N/A
0.052
-0.13
EBITDA
737.78 B
N/A
N/A
N/A
5.93 B
42.2 B
N/A
772.1 B
(666.94 M)
Operating Margin
0.32
N/A
N/A
N/A
0.11
0.15
N/A
0.0753
-0.0495
Current Valuation
58.92 T
N/A
N/A
N/A
65.74 B
232.39 B
N/A
1.77 T
147.73 B
Price To Book
6.92
N/A
N/A
N/A
N/A
N/A
N/A
0.51
0.92
Retained Earnings
N/A
N/A
N/A
N/A
20.26 B
41.32 B
N/A
N/A
N/A
Current Asset
N/A
N/A
N/A
N/A
52.11 B
36.24 B
N/A
N/A
N/A
Beta
0.58
N/A
N/A
N/A
1.19
0.87
N/A
1.41
1.41
Number Of Employees
10
N/A
N/A
N/A
77
611
N/A
3.67 K
116
Shares Outstanding
71.17 M
N/A
N/A
N/A
12.75 M
8.66 M
N/A
410.89 M
45.15 M
Cash Flow From Operations
454.6 B
N/A
N/A
N/A
(555.84 M)
25.55 B
N/A
1.75 T
(2.67 B)
Annual Yield
N/A
N/A
N/A
N/A
N/A
0.0149
N/A
N/A
0.0106
Total Debt
1.11 T
N/A
N/A
N/A
335.03 M
3.44 B
N/A
906.39 B
16.56 B
Return On Equity
0.0751
N/A
N/A
N/A
2.2
28.59
N/A
0.15
-0.27
Z Score
30.6
N/A
N/A
N/A
N/A
37.6
N/A
1.2
2.4
Return On Asset
0.0422
N/A
N/A
N/A
0.0845
0.14
N/A
0.0427
-0.0144
Book Value Per Share
N/A
N/A
N/A
N/A
4430.58
N/A
N/A
N/A
N/A
Current Liabilities
N/A
N/A
N/A
N/A
30.67 B
11.77 B
N/A
N/A
N/A
Total Asset
7.97 T
N/A
N/A
N/A
45.54 B
206.24 B
N/A
10.46 T
195.06 B
Target Price
1000000.0
N/A
N/A
N/A
N/A
29000.0
N/A
5592.0
N/A
Debt To Equity
N/A
N/A
N/A
N/A
86.3
0.06
N/A
N/A
N/A
Last Dividend Paid
N/A
N/A
N/A
N/A
N/A
70.0
N/A
N/A
20.0
Shares Owned By Institutions
13.8
N/A
N/A
N/A
N/A
2.03
N/A
13.88
0.49
Market Capitalization
57.3 T
N/A
N/A
N/A
56.66 B
211.25 B
N/A
1.84 T
82.45 B
Price To Earning
N/A
N/A
N/A
N/A
27.86
18.24
N/A
N/A
N/A
Price To Sales
23.45
N/A
N/A
N/A
0.79
0.64
N/A
0.19
1.04
Net Income
393.59 B
N/A
N/A
N/A
4.85 B
38.97 B
N/A
484.68 B
(3.02 B)
Earnings Per Share
2417.83
N/A
N/A
N/A
N/A
N/A
N/A
317.0
N/A
Shares Owned By Insiders
75.18
N/A
N/A
N/A
54.82
23.75
N/A
50.9
37.8
Revenue
1.57 T
N/A
N/A
N/A
49.99 B
304.49 B
N/A
8.69 T
163.69 B
Working Capital
N/A
N/A
N/A
N/A
21.44 B
24.47 B
N/A
N/A
N/A
Cash And Equivalents
N/A
N/A
N/A
N/A
1.31 B
42.42 B
N/A
N/A
N/A
Cash Per Share
N/A
N/A
N/A
N/A
713.31
N/A
N/A
N/A
N/A
Gross Profit
723.35 B
N/A
N/A
N/A
11.73 B
60.72 B
N/A
1.24 T
18.59 B
Day Typical Price
935000.0
18810.0
508.33
22666.67
1442.67
15596.67
3543.33
3708.33
1266.67
Accumulation Distribution
3186.35
637.19
98158.46
834.5
0.0028
25878.93
20505.12
41368.32
1484.34
Market Facilitation Index
0.38
0.025
0.0
0.0333
4.0
0.0022
3.0E-4
1.0E-4
0.001
Daily Balance Of Power
(0.85)
0.9455
0.7059
(0.12)
1.0
0.4421
(0.14)
0.2143
0.5349
Period Momentum Indicator
(29,000)
520.0
24.0
(100.00)
4.0
420.0
(20.00)
30.0
23.0
Rate Of Daily Change
0.97
1.03
1.05
1.0
1.0
1.03
0.99
1.01
1.02
Day Median Price
938000.0
18725.0
505.0
22600.0
1442.0
15535.0
3557.5
3690.0
1260.5
Price Action Indicator
(23,500)
515.0
22.0
150.0
4.0
395.0
(52.50)
70.0
30.0
Coefficient Of Variation
2669.98
(4,684)
17029.44
(1,177)
(719.97)
(1,891)
3919.38
(2,645)
(961.69)
Mean Deviation
0.8724
0.9073
2.17
2.65
0.5783
2.5
2.29
1.37
0.9568
Jensen Alpha
0.0296
(0.02)
(0.08)
(0.31)
(0.15)
(0.13)
(0.01)
(0.14)
(0.17)
Total Risk Alpha
(0.18)
(0.24)
(0.47)
(0.87)
(0.29)
(0.67)
(0.42)
(0.39)
(0.38)
Sortino Ratio
(0.04)
N/A
(0.04)
N/A
N/A
N/A
(0.02)
N/A
N/A
Downside Variance
3.34
N/A
8.96
N/A
N/A
N/A
7.64
N/A
N/A
Standard Deviation
1.42
1.29
3.06
3.59
0.9554
3.15
3.13
1.96
1.41
Kurtosis
1.96
2.04
2.76
2.4
5.04
0.0129
2.37
2.92
5.5
Potential Upside
2.57
1.65
4.45
5.62
1.18
6.14
5.8
3.48
2.03
Treynor Ratio
0.3751
0.335
0.0105
4.89
(1.89)
0.4164
0.0994
(0.17)
(2.05)
Maximum Drawdown
8.27
7.39
16.54
22.9
5.64
14.9
18.43
10.51
6.43
Variance
2.02
1.66
9.36
12.92
0.9128
9.92
9.82
3.85
2.0
Market Risk Adjusted Performance
0.3851
0.345
0.0205
4.9
(1.88)
0.4264
0.1094
(0.16)
(2.04)
Risk Adjusted Performance
0.0332
(0.01)
0.012
(0.06)
(0.10)
(0.03)
0.0271
(0.02)
(0.07)
Skewness
0.3104
0.2359
0.7594
(0.51)
(1.41)
0.184
0.9862
0.908
1.03
Semi Deviation
1.1
N/A
2.85
N/A
N/A
N/A
2.62
N/A
N/A
Information Ratio
(0.05)
(0.12)
(0.04)
(0.12)
(0.27)
(0.09)
(0.02)
(0.10)
(0.19)
Value At Risk
(2.24)
(2.71)
(5.24)
(5.73)
(1.52)
(5.05)
(4.19)
(3.02)
(2.27)
Expected Short fall
(1.49)
N/A
(2.19)
N/A
N/A
N/A
(2.52)
N/A
N/A
Downside Deviation
1.83
N/A
2.99
N/A
N/A
N/A
2.76
N/A
N/A
Semi Variance
1.21
N/A
8.1
N/A
N/A
N/A
6.88
N/A
N/A

Samsung Biologics Competition Performance Charts

Five steps to successful analysis of Samsung Biologics Competition

Samsung Biologics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Samsung Biologics in relation to its competition. Samsung Biologics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Samsung Biologics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Samsung Biologics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Samsung Biologics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Samsung Biologics position

In addition to having Samsung Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Medical Equipment Thematic Idea Now

Medical Equipment
Medical Equipment Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Medical Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Medical Equipment Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Samsung Stock

Samsung Biologics financial ratios help investors to determine whether Samsung Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Samsung with respect to the benefits of owning Samsung Biologics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY